Non Hodgkin Lymphoma News and Research

RSS

Gilead and Kite to present data from cell therapy research at 25th EHA Virtual Congress

Gilead Sciences, Inc. and Kite, a Gilead Company, are pleased to support the Virtual Edition of the 25th European Hematology Association Annual Congress, taking place 11–21 June 2020.

From Gilead Sciences, Inc. 10 Jun 2020

Phase III clinical trial shows benefit of rituximab for pediatric Burkitt lymphoma

Results of the phase III Inter-B-NHL-ritux 2010 clinical trial reported today in the New England Journal of Medicine show 95 percent three-year survival for pediatric patients with advanced B-cell non-Hodgkin lymphoma treated with the addition of anti-cancer immunotherapy rituximab to standard chemotherapy.

3 Jun 2020

Scientist explore potential drugs to prevent cell resistance in different types of cancer

Cancer therapy may shrink the tumor of a patient, and the patient may feel better. But unseen on a CT scan or MR image, some of the cells are undergoing ominous changes.

29 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

EPFL scientists identify new therapeutic target for Non-Hodgkin lymphoma

Non-Hodgkin lymphoma is a group of cancers that originate in the lymph nodes and affect white blood cells of the immune system called B cells.

23 Apr 2020

Investigational CAR-T therapy for Hodgkin lymphoma receives fast-track designation from FDA

Based on proof-of-concept results from clinical trials at University of North Carolina Lineberger Comprehensive Cancer Center and Baylor College of Medicine, an investigational cellular immunotherapy for Hodgkin lymphoma has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration.

9 Mar 2020

Study: Five-year survival rate for adolescents and young adults with cancer has improved

The five-year survival rate for adolescents and young adults with cancer has significantly improved from 1975 to 2005 in the United States overall, but this was not the case for all cancers, according to a report in the Journal of the National Cancer Institute.

3 Mar 2020

Study finds improvements in survival rates for all cancers in young adults

A new study in the Journal of the National Cancer Institute, published by Oxford University Press, finds improvements in five-year survival rates for all cancers in young adults.

3 Mar 2020

Cancer risk in psoriatic patients

A new study published in February 2020 in the journal JAMA Dermatology reports that there is a 21% increased risk of cancer in patients with psoriasis, but not with psoriatic arthritis alone.

19 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

New discovery could enable scientists to fine-tune activity of cancer-killing immune cells

A discovery by University of North Carolina Lineberger Comprehensive Cancer Center researchers could allow scientists to fine-tune genetically engineered immune cells to heighten their killing power against tumors or to decrease their activity level in the case of severe side effects.

31 Jan 2020

Study shows potential new approach to treating two common subtypes of lymphoma

A study at The University of Texas MD Anderson Cancer Center demonstrated a potential new approach to treating two of the most common subtypes of lymphoma through manipulation of molecular programs controlled by the cAMP-response element binding protein.

8 Jan 2020

Recommended amounts of physical activity associated with reduced risk for seven cancers

A pooled analysis of nine prospective studies involving more than 750,000 adults finds that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers, with several cancer types having a 'dose/response' relationship.

27 Dec 2019

Novel and targeted cellular product causes cell death in non-Hodgkin lymphoma models

Investigators at Rutgers Cancer Institute of New Jersey have found that a treatment based on a novel cellular product programmed to deliver an overabundance of chimeric antigen receptor causes cell death in non-Hodgkin lymphoma models that are sensitive or resistant to standard therapies.

16 Dec 2019

$Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission$

Experimental immunotherapy can put patients with relapsed or refractory lymphoma into remission

A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.

8 Dec 2019

Study: Calcium signaling can help address drug resistance to non-Hodgkin lymphoma

Gene expression profiling and other analyses conducted by Rutgers Cancer Institute of New Jersey researchers and colleagues examining drug resistance to a common antibody therapy for non-Hodgkin lymphoma have identified calcium signaling as a novel and exploitable target in overcoming this treatment obstacle.

3 Dec 2019

Radiation from CT scans can increase risk of leukemia, thyroid cancer

A new study in JNCI Cancer Spectrum finds that exposure to radiation from CT scans is associated with higher risks of developing thyroid cancer and leukemia.

19 Nov 2019

Simple blood test can better identify patients at risk of relapse for B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a cancer that begins in certain immune system cells and can occur almost anywhere in the body. More than 28,000 people are diagnosed with DLBCL each year.

21 Oct 2019

Scientists use CAR-T cells to reverse cardiac fibrosis

Scientists have used CAR-T cell therapy to treat cardiac fibrosis, a key part of heart disease and cardiac arrest.

12 Sep 2019

Cancer survivors could be at greater risk of cardiovascular diseases

Over the last few decades, medical progress has led to the survival of many more people with cancer. However, a new study published in The Lancet shows that this cohort has a higher risk of cardiovascular disease (CVD) than controls without cancer, due to a number of reasons.

21 Aug 2019